Bristol-Myers Squibb Co. (BMY)

60.89
NYSE : Health Technology
Prev Close 61.11
Day Low/High 60.80 / 61.59
52 Wk Low/High 49.96 / 70.05
Avg Volume 6.30M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 99.72B
EPS 0.60
P/E Ratio 254.62
Div & Yield 1.60 (2.64%)

Latest News

I See More Volatility Ahead

Although it would not surprise me if we see a rally attempt on Tuesday.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2018, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab), and important regulatory progress in the company's Immuno-Oncology...

Bristol-Myers Squibb And Tsinghua University Announce Collaboration To Accelerate Early Research Into Potential Therapies For Autoimmune Diseases And Cancer

Bristol-Myers Squibb And Tsinghua University Announce Collaboration To Accelerate Early Research Into Potential Therapies For Autoimmune Diseases And Cancer

Bristol-Myers Squibb Company (NYSE: BMY) and Tsinghua University, have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.

Bristol-Myers Squibb Announces Departure Of Chief Commercial Officer

Bristol-Myers Squibb Announces Departure Of Chief Commercial Officer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3, 2018, to pursue another opportunity.

Bristol-Myers Squibb And Gritstone Oncology Announce Clinical Research Collaboration To Evaluate Novel Immunotherapy Approach In Advanced Solid Tumors

Bristol-Myers Squibb And Gritstone Oncology Announce Clinical Research Collaboration To Evaluate Novel Immunotherapy Approach In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone's personalized neoantigen immunotherapy, GRANITE-001,...

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

Bristol-Myers Squibb's Opdivo® (nivolumab) Low-Dose Yervoy® (ipilimumab) Is The First Immuno-Oncology Combination Approved For MSI-H/dMMR MCRC Patients Who Progressed Following Treatment With A Fluoropyrimidine, Oxaliplatin And...

Bristol-Myers Squibb's Opdivo® (nivolumab) Low-Dose Yervoy® (ipilimumab) Is The First Immuno-Oncology Combination Approved For MSI-H/dMMR MCRC Patients Who Progressed Following Treatment With A Fluoropyrimidine, Oxaliplatin And...

Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval from the U.

Only Immuno-Oncology Combination Therapy Approved By Health Canada As First-Line Treatment For Advanced Or Metastatic Renal Cell Carcinoma

Only Immuno-Oncology Combination Therapy Approved By Health Canada As First-Line Treatment For Advanced Or Metastatic Renal Cell Carcinoma

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) combination is the first and only treatment to show significantly superior overall survival versus current standard of care in intermediate- and poor-risk advanced or metastatic renal cell carcinoma 1 MONTREAL,...

European Commission Approves Expanded Indication For Sprycel (dasatinib) To Include Treatment Of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase

European Commission Approves Expanded Indication For Sprycel (dasatinib) To Include Treatment Of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has expanded the indication for Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia...

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended expanded approval of the current indications for Opdivo (nivolumab) to include the...

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Jim Cramer weighs in on Under Armour, Cognex, Novocure, FireEye, Weight Watchers, Bristol-Meyers Squibb and Chegg.

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

Jim Cramer explains why the fulcrum for the financial markets is growth -- not tariffs, or the Fed, or interest rates.

"Making My Mom Proud On And Off The Football Field Is How I Harness My Unique Power To Rise Up Against Cancer." - Dak Prescott, Quarterback Of The Dallas Cowboys (Photo: Business Wire)

"Making My Mom Proud On And Off The Football Field Is How I Harness My Unique Power To Rise Up Against Cancer." - Dak Prescott, Quarterback Of The Dallas Cowboys (Photo: Business Wire)

Dak Prescott, quarterback of the Dallas Cowboys, Eric Stonestreet, star of television's hit comedy "Modern Family," and Tia Mowry of YouTube's "Tia Mowry's Quick Fix" are teaming up with Bristol-Myers Squibb to launch the Ready.

Eight Stocks That Are Poised to Change Direction

Eight Stocks That Are Poised to Change Direction

Harley-Davidson is among these names showing technical reversal patterns over the past week.

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

Tesla, Boeing and Merck Among Companies Hurt by Latest Tariffs

The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.

China National Drug Administration Approves Country's First Immuno-Oncology Agent, Opdivo (nivolumab Injection), For Previously Treated Non-Small Cell Lung Cancer (NSCLC)

China National Drug Administration Approves Country's First Immuno-Oncology Agent, Opdivo (nivolumab Injection), For Previously Treated Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the China National Drug Administration (CNDA) has approved Opdivo (nivolumab injection) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior...

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.

Bristol-Myers Squibb To Present New Research Findings On The Treatment Of Patients With Early Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2018)

Bristol-Myers Squibb To Present New Research Findings On The Treatment Of Patients With Early Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2018)

Bristol-Myers Squibb Company (NYSE: BMY) today confirmed that 31 abstracts demonstrating The Company's immunoscience-research focus as well as how ORENCIA ® (abatacept) therapy may impact diverse patient subgroups will be presented at the Annual European...

Bristol-Myers Squibb To Take Part In Goldman Sachs 39th Annual Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Goldman Sachs 39th Annual Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018, in Rancho Palos Verdes, CA.

Bristol-Myers Squibb To Announce Results For Second Quarter 2018 On July 26

Bristol-Myers Squibb To Announce Results For Second Quarter 2018 On July 26

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2018 on Thursday, July 26, 2018.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

Opdivo (nivolumab) 3 Mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 Mg/kg For Broad Range Of Patients With Resected Stage III Or IV Melanoma

Opdivo (nivolumab) 3 Mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 Mg/kg For Broad Range Of Patients With Resected Stage III Or IV Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence...

Preliminary Data For NKTR-214 In Combination With Opdivo (nivolumab) For Patients With Stage IV Metastatic Melanoma, Renal Cell Carcinoma, And Urothelial Cancers Presented At ASCO 2018

Preliminary Data For NKTR-214 In Combination With Opdivo (nivolumab) For Patients With Stage IV Metastatic Melanoma, Renal Cell Carcinoma, And Urothelial Cancers Presented At ASCO 2018

Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation

U.S. Food And Drug Administration Lifts Partial Clinical Hold On Opdivo (nivolumab)-based Combination Study In Multiple Myeloma

U.S. Food And Drug Administration Lifts Partial Clinical Hold On Opdivo (nivolumab)-based Combination Study In Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.

Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant And Sustained Health-Related Quality Of Life Improvements In Intermediate- And Poor-Risk Patients With Advanced Renal Cell Carcinoma In CheckMate -214 Study

Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant And Sustained Health-Related Quality Of Life Improvements In Intermediate- And Poor-Risk Patients With Advanced Renal Cell Carcinoma In CheckMate -214 Study

Bristol-Myers Squibb Company (NYSE:BMY) today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC) treated with the Immuno-Oncology combination...

Bristol-Myers Squibb To Hold Investor Event To Discuss ASCO Highlights

Bristol-Myers Squibb To Hold Investor Event To Discuss ASCO Highlights

Bristol-Myers Squibb Company (NYSE:BMY) will hold an investor event on Monday, June 4, 2018 at 8:30 p.

TheStreet Quant Rating: C+ (Hold)